Intracerebral bleeding in patients on antithrombotic agents

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 8, 2013, Pages 963-971

  Veltkamp, Roland ^a   Rizos, Timolaos ^a   Horstmann, Solveig ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

intracerebral hemorrhage; oral anticoagulation; warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; APOLIPOPROTEIN E2; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DABIGATRAN; FRESH FROZEN PLASMA; PHENPROCOUMON; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBOPLASTIN; VITAMIN K GROUP; WARFARIN;

ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ARTERY RUPTURE; ARTICLE; BLOOD CLOTTING; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST MEDIUM EXTRAVASATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; EMERGENCY TREATMENT; FOLLOW UP; GENETIC ASSOCIATION; HEART ATRIUM APPENDAGE; HEART FAILURE; HEART VALVE PROSTHESIS; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LEUKOARAIOSIS; LUNG EDEMA; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; SMOKING; THROMBIN TIME; THROMBOCYTE ACTIVATION; VASCULAR AMYLOIDOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CEREBRAL HEMORRHAGE; FACTOR VIIA; HEMOSTATICS; HUMANS; PROGNOSIS; RECOMBINANT PROTEINS; RISK FACTORS; SURVIVAL RATE;

EID: 84887018579     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1357506     Document Type: Article

References (125)

1. Morgenstern L. B., Hemphill J. C., Anderson C., et al. Guideline for Healthcare Professionals from the American Heart AHA/ASA Guideline Intracerebral Hemorrhage A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke: 2010; 41 2108 2129
2. Steiner T., Kaste M., Forsting M., et al. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracreebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis: 2006; 22 4 294 316
3. Sacco S., Marini C., Toni D., Olivieri L., Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke: 2009; 40 2 394 399
4. Fogelholm R., Murros K., Rissanen A., Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry: 2005; 76 11 1534 1538 (Pubitemid 41531701)
5. Broderick J. P., Brott T. G., Duldner J. E., Tomsick T., Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke: 1993; 24 7 987 993 (Pubitemid 23201455)
6. Mendelow A. D., Gregson B. A., Fernandes H. M., et al. STICH investigators Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet: 2005; 365 9457 387 397 (Pubitemid 40179225)
7. Ariesen M. J., Claus S. P., Rinkel G. J., Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke: 2003; 34 8 2060 2065 (Pubitemid 36944806)
8. O'Donnell M. J., Xavier D., Liu L., et al. INTERSTROKE investigators Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet: 2010; 376 9735 112 123
9. Rosand J., Hylek E. M., O'Donnell H. C., Greenberg S. M. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology: 2000; 55 7 947 951
10. Charidimou A., Baron J. C., Werring D. J. Transient focal neurological episodes, cerebral amyloid angiopathy, and intracerebral hemorrhage risk: looking beyond TIAs. Int J Stroke: 2013; 8 2 105 108
11. Charidimou A., Meegahage R., Fox Z., et al. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study. J Neurol Neurosurg Psychiatry: 2013; 84 6 624 629
12. Hirsh J., Guyatt G., Albers G. W., et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 6 Suppl 110S 112S (Pubitemid 351892962)
13. Büller H. R., Gallus A. S., Pillion G., Prins M. H., Raskob G. E. Cassiopea Investigators Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet: 2012; 379 9811 123 129
14. Kearon C., Gent M., Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med: 1999; 340 12 901 907 (Pubitemid 29141050)
15. Gage B. F., Waterman A. D., Shannon W., Boechler M., Rich M. W., Radford M. J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA: 2001; 285 22 2864 2870 (Pubitemid 32537350)
16. Rost S., Fregin A., Ivaskevicius V., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature: 2004; 427 6974 537 541 (Pubitemid 38209110)
17. Li T., Chang C-Y, Jin D-Y, Lin P. J., Khvorova A., Stafford D. W. Identification of the gene for vitamin K epoxide reductase. Nature: 2004; 427 6974 541 544 (Pubitemid 38209111)
18. Hirsh J., Anand S. S., Halperin J. L., Fuster V. American Heart Association Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation: 2001; 103 24 2994 3018 (Pubitemid 32578141)
19. Hart R. G., Pearce L. A., Aguilar M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med: 2007; 146 12 857 867 (Pubitemid 351650486)
20. Ogilvie I. M., Newton N., Welner S. A., Cowell W., Lip G. Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med: 2010; 123 7 638 645, e4
21. Taggar J. S., Lip G. YH. Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range. Curr Med Res Opin: 2008; 24 5 1455 1458 (Pubitemid 351741579)
22. Schwarz U. I., Ritchie M. D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med: 2008; 358 10 999 1008 (Pubitemid 351347099)
23. Arnold M-L, Grond-Ginsbach C., Kloss M., et al. Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients. Cerebrovasc Dis: 2009; 28 5 468 471
24. Oldenburg J., Marinova M., Müller-Reible C., Watzka M. The vitamin K cycle. Vitam Horm: 2008; 78 35 62
25. Steiner T., Rosand J., Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke: 2006; 37 1 256 262 (Pubitemid 43732088)
26. Levine M. N., Raskob G., Beyth R. J., Kearon C., Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest: 2004; 126 3, Suppl 287S 310S (Pubitemid 39297958)
27. Wallvik J., Själander A., Johansson L., Bjuhr O., Jansson J. H. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care: 2007; 25 2 123 128 (Pubitemid 46752224)
28. Eisert W. G., Hauel N., Stangier J., Wienen W., Clemens A., van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol: 2010; 30 10 1885 1889
29. Weitz J. I. New oral anticoagulants in development. Thromb Haemost: 2010; 103 1 62 70
30. Weitz J. I. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res: 2011; 127 02 S5 S12
31. Hohnloser S. H., Crijns H. J., van Eickels M., et al. ATHENA Investigators Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med: 2009; 360 7 668 678
32. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
33. Wolf P. A., Abbott R. D., Kannel W. B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med: 1987; 147 9 1561 1564 (Pubitemid 17138836)
34. Heeringa J., van der Kuip D. AM, Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J: 2006; 27 8 949 953
35. Go A. S., Hylek E. M., Phillips K. A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA: 2001; 285 18 2370 2375 (Pubitemid 32424106)
36. Flaherty M. L., Kissela B., Woo D., et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology: 2007; 68 2 116 121 (Pubitemid 46071894)
37. Franke C. L., de Jonge J., van Swieten J. C., Op de Coul A. A., van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke: 1990; 21 5 726 730 (Pubitemid 20180795)
38. Flibotte J. J., Hagan N., O'Donnell J., Greenberg S. M., Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology: 2004; 63 6 1059 1064 (Pubitemid 39287915)
39. Rosand J., Eckman M. H., Knudsen K. A., Singer D. E., Greenberg S. M. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med: 2004; 164 8 880 884 (Pubitemid 38520629)
40. Flibotte J. J., Hagan N., O'Donnell J., Greenberg S. M., Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology: 2004; 63 6 1059 1064 (Pubitemid 39287915)
41. Flaherty M. L., Kissela B., Woo D., et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology: 2007; 68 2 116 121 (Pubitemid 46071894)
42. Lip G. YH. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost: 2010; 103 4 683 685
43. Torn M., Bollen W. L., van der Meer F. J., van der Wall E. E., Rosendaal F. R. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med: 2005; 165 13 1527 1532 (Pubitemid 41058034)
44. Fisher C. M. Cerebral miliary aneurysms in hypertension. Am J Pathol: 1972; 66 2 313 330
45. Vinters H. V. Cerebral amyloid angiopathy. A critical review. Stroke: 1987; 18 2 311 324 (Pubitemid 17059655)
46. Hart R. G., Tonarelli S. B., Pearce L. A. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke: 2005; 36 7 1588 1593 (Pubitemid 40967537)
47. Schulman S., Beyth R. J., Kearon C., Levine M. N. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 6, Suppl 257S 298S (Pubitemid 351892969)
48. Hart R. G. What causes intracerebral hemorrhage during warfarin therapy? Neurology: 2000; 55 7 907 908
49. Dequatre-Ponchelle N., Hénon H., Pasquini M., et al. Vitamin K antagonists-associated cerebral hemorrhages: what are their characteristics? Stroke: 2013; 44 2 350 355
50. Smith E. E., Rosand J., Knudsen K. A., Hylek E. M., Greenberg S. M. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology: 2002; 59 2 193 197 (Pubitemid 34779176)
51. Hylek E. M., Go A. S., Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med: 2003; 349 11 1019 1026 (Pubitemid 37087616)
52. Lee G. H., Kwon S. U., Kang D. W. Warfarin-induced intracerebral hemorrhage associated with microbleeds. J Clin Neurol: 2008; 4 3 131 133
53. Gasse C., Hollowell J., Meier C. R., Haefeli W. E. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost: 2005; 94 3 537 543 (Pubitemid 41300849)
54. Holbrook A. M., Pereira J. A., Labiris R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med: 2005; 165 10 1095 1106 (Pubitemid 40720733)
55. Granger C. B., Alexander J. H., McMurray J. JV., et al. ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
56. Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
57. Fazekas F., Kleinert R., Roob G., et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol: 1999; 20 4 637 642 (Pubitemid 30429021)
58. Guo L. F., Wang G., Zhu X. Y., Liu C., Cui L. Comparison of ESWAN, SWI-SPGR, and 2D T2*-Weighted GRE sequence for depicting cerebral microbleeds. Clin Neuroradiol: 2013; 23 2 121 127
59. Tanaka A., Ueno Y., Nakayama Y., Takano K., Takebayashi S. Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. Stroke: 1999; 30 8 1637 1642 (Pubitemid 29379616)
60. Naka H., Nomura E., Takahashi T., et al. Combinations of the presence or absence of cerebral microbleeds and advanced white matter hyperintensity as predictors of subsequent stroke types. AJNR Am J Neuroradiol: 2006; 27 4 830 835 (Pubitemid 44897731)
61. Roob G., Schmidt R., Kapeller P., Lechner A., Hartung H. P., Fazekas F. MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology: 1999; 52 5 991 994 (Pubitemid 29161609)
62. Lovelock C. E., Cordonnier C., Naka H., et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke: 2010; 41 6 1222 1228
63. Fan Y. H., Zhang L., Lam W. W., Mok V. C., Wong K. S. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke: 2003; 34 10 2459 2462 (Pubitemid 37221963)
64. Lee S. H., Ryu W. S., Roh J. K. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology: 2009; 72 2 171 176
65. Biffi A., Sonni A., Anderson C. D., et al. International Stroke Genetics Consortium Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol: 2010; 68 6 934 943
66. Woo D., Sauerbeck L. R., Kissela B. M., et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke: 2002; 33 5 1190 1195 (Pubitemid 34517033)
67. Biffi A., Anderson C. D., Jagiella J. M., et al. International Stroke Genetics Consortium APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol: 2011; 10 8 702 709
68. Pisters R., Lane D. A., Nieuwlaat R., de Vos C. B., Crijns H. J., Lip G. Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest: 2010; 138 5 1093 1100
69. Friberg L., Rosenqvist M., Lip G. Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J: 2012; 33 12 1500 1510
70. Brott T., Broderick J., Kothari R., et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke: 1997; 28 1 1 5 (Pubitemid 27039454)
71. Davis S. M., Broderick J., Hennerici M., et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology: 2006; 66 8 1175 1181 (Pubitemid 43739699)
72. Yasaka M., Minematsu K., Naritomi H., Sakata T., Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost: 2003; 89 2 278 283 (Pubitemid 36227279)
73. Huttner H. B., Schellinger P. D., Hartmann M., et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke: 2006; 37 6 1465 1470 (Pubitemid 44305727)
74. Biffi A., Battey T. W., Ayres A. M., et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology: 2011; 77 20 1840 1846
75. Mayer S. A., Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol: 2005; 4 10 662 672 (Pubitemid 41317301)
76. Greenberg C. H., Frosch M. P., Goldstein J. N., Rosand J., Greenberg S. M. Modeling intracerebral hemorrhage growth and response to anticoagulation. PLoS ONE: 2012; 7 10 e48458
77. Demchuk A. M., Dowlatshahi D., Rodriguez-Luna D., et al. PREDICT/Sunnybrook ICH CTA study group Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol: 2012; 11 4 307 314
78. Xi G., Keep R. F., Hoff J. T. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol: 2006; 5 1 53 63 (Pubitemid 41790696)
79. Aronowski J., Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke: 2011; 42 6 1781 1786
80. Xi G., Fewel M. E., Hua Y., Thompson B. G. Jr, Hoff J. T., Keep R. F. Intracerebral hemorrhage: pathophysiology and therapy. Neurocrit Care: 2004; 1 1 5 18 (Pubitemid 41278374)
81. Wang J., Doré S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab: 2007; 27 5 894 908 (Pubitemid 46659028)
82. Ferreira C. N., Vieira L. M., Dusse L. MS., et al. Evaluation of the blood coagulation mechanism and platelet aggregation in individuals with mechanical or biological heart prostheses. Blood Coagul Fibrinolysis: 2002; 13 2 129 134 (Pubitemid 35001676)
83. Rizos T., Jenetzky E., Herweh C., et al. Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage. Ann Neurol: 2010; 67 6 788 793
84. Rizos T., Jenetzky E., Herweh C., Unterberg A., Hacke W., Veltkamp R. Fast point-of-care coagulometer guided reversal of oral anticoagulation at the bedside hastens management of acute subdural hemorrhage. Neurocrit Care: 2010; 13 3 321 325
85. Freeman W. D., Brott T. G., Barrett K. M., et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc: 2004; 79 12 1495 1500 (Pubitemid 39578872)
86. Butler A. C., Tait R. C. Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev: 1998; 12 1 35 44 (Pubitemid 28205974)
87. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 160S 198S (Pubitemid 351892967)
88. Baglin T. P., Keeling D. M., Watson H. G. British Committee for Standards in Haematology Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol: 2006; 132 3 277 285 (Pubitemid 43381534)
89. Boulis N. M., Bobek M. P., Schmaier A., Hoff J. T. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery: 1999; 45 5 1113 1118, discussion 1118-1119
90. Freeman W. D., Aguilar M. I. Management of warfarin-related intracerebral hemorrhage. Expert Rev Neurother: 2008; 8 2 271 290 (Pubitemid 351284436)
91. Kessler C. M. Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? J Thromb Haemost: 2006; 4 5 963 966
92. Foerch C., Arai K., Van Cott E. M., van Leyen K., Lo E. H. Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage. J Cereb Blood Flow Metab: 2009; 29 5 1015 1021
93. Illanes S., Zhou W., Schwarting S., Heiland S., Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke: 2011; 42 1 191 195
94. Beeck H., Hellstern P. In vitro characterization of solvent/detergent- treated human plasma and of quarantine fresh frozen plasma. Vox Sang: 1998; 74 01 219 223 (Pubitemid 28379661)
95. Hanley J. P. Warfarin reversal. J Clin Pathol: 2004; 57 11 1132 1139 (Pubitemid 39486516)
96. Bianco C. Choice of human plasma preparations for transfusion. Transfus Med Rev: 1999; 13 2 84 88 (Pubitemid 29185000)
97. Leissinger C. A., Blatt P. M., Hoots W. K., Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol: 2008; 83 2 137 143
98. Junagade P., Grace R., Gover P. Fixed dose prothrombin complex concentrate for the reversal of oral anticoagulation therapy. Hematology: 2007; 12 5 439 440 (Pubitemid 47487854)
99. Köhler M., Hellstern P., Lechler E., Uberfuhr P., Müller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost: 1998; 80 3 399 402 (Pubitemid 28438732)
100. Appelboam R., Thomas E. O. Warfarin and intracranial haemorrhage. Blood Rev: 2009; 23 1 1 9
101. Steiner T., Freiberger A., Griebe M., et al. International normalised ratio normalisation in patients with coumarin-related intracranial haemorrhages-the INCH trial: a randomised controlled multicentre trial to compare safety and preliminary efficacy of fresh frozen plasma and prothrombin complex. Int J Stroke: 2011; 6 3 271 277
102. Broderick J., Connolly S., Feldmann E., et al. American Heart Association American Stroke Association Stroke Council High Blood Pressure Research Council Quality of Care and Outcomes in Research Interdisciplinary Working Group Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke: 2007; 38 6 2001 2023 (Pubitemid 46850654)
103. Mayer S. A., Brun N. C., Begtrup K., et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med: 2005; 352 8 777 785
104. Mayer S. A., Brun N. C., Begtrup K., et al. FAST Trial Investigators Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med: 2008; 358 20 2127 2137 (Pubitemid 351679599)
105. Erhardtsen E., Nony P., Dechavanne M., Ffrench P., Boissel J. P., Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis: 1998; 9 8 741 748 (Pubitemid 29144978)
106. Sorensen B., Johansen P., Nielsen G. L., Sorensen J. C., Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis: 2003; 14 5 469 477 (Pubitemid 36951864)
107. Brody D. L., Aiyagari V., Shackleford A. M., Diringer M. N. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care: 2005; 2 3 263 267 (Pubitemid 41112397)
108. Zhou W., Schwarting S., Illanes S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke: 2011; 42 12 3594 3599
109. Zhou W., Zorn M., Nawroth P., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke: 2013; 44 3 771 778
110. Lauer A., Cianchetti F. A., Van Cott E. M., et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation: 2011; 124 15 1654 1662
111. Steiner T., Bösel J. Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage. Stroke: 2010; 41 2 402 409
112. Qureshi A. I., Tuhrim S., Broderick J. P., Batjer H. H., Hondo H., Hanley D. F. Spontaneous intracerebral hemorrhage. N Engl J Med: 2001; 344 19 1450 1460 (Pubitemid 32402103)
113. Alberts M. J., Eikelboom J. W., Hankey G. J. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol: 2012; 11 12 1066 1081
114. Bauer K. A. Reversal of antithrombotic agents. Am J Hematol: 2012; 87 01 S119 S126
115. van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost: 2010; 103 6 1116 1127
116. Eerenberg E. S., Kamphuisen P. W., Sijpkens M. K., Meijers J. C., Buller H. R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation: 2011; 124 14 1573 1579
117. Steiner T. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: yes. Stroke: 2011; 42 12 3661 3662
118. Veltkamp R., Jüttler E., Pfefferkorn T., Purrucker J., Ringleb P. [Current registry studies of acute ischemic stroke]. Nervenarzt: 2012; 83 10 1270 1274
119. Khadzhynov D., Wagner F., Formella S., et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost: 2013; 109 4 596 605
120. Kaatz S., Kouides P. A., Garcia D. A., et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol: 2012; 87 01 S141 S145
121. Vigué B., Ract C., Tremey B., et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med: 2007; 33 4 721 725 (Pubitemid 46474890)
122. Andersen K. K., Olsen T. S., Dehlendorff C., Kammersgaard L. P. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. Stroke: 2009; 40 6 2068 2072
123. Broderick J., Connolly S., Feldmann E., et al. American Heart Association American Stroke Association Stroke Council High Blood Pressure Research Council Quality of Care and Outcomes in Research Interdisciplinary Working Group Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke: 2007; 38 6 2001 2023 (Pubitemid 46850654)
124. Eckman M. H., Rosand J., Knudsen K. A., Singer D. E., Greenberg S. M. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke: 2003; 34 7 1710 1716 (Pubitemid 36842632)
125. Holmes D. R., Reddy V. Y., Turi Z. G., et al. PROTECT AF Investigators Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet: 2009; 374 9689 534 542